» Articles » PMID: 36571609

Contrast-enhanced Computed Tomography Radiomics in Predicting Primary Site Response to Neoadjuvant Chemotherapy in High-risk Neuroblastoma

Overview
Publisher Springer
Date 2022 Dec 26
PMID 36571609
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To explore the clinical value of contrast-enhanced computed tomography (CECT) radiomics in predicting primary site response to neoadjuvant chemotherapy in high-risk neuroblastoma.

Materials And Methods: Seventy patients were retrospectively included and separated into very good partial response (VGPR) group and non-VGPR group according to the changes in primary tumor volume. The clinical features with statistical difference between the two groups were used to construct the clinical models using a logistic regression (LR) algorithm. The radiomics models based on different radiomics features selected by Kruskal-Wallis (KW) test and recursive feature elimination (RFE) were established using support vector machine (SVM) and LR algorithms. The radiomics score (Radscore) and clinical features were integrated into the combined models. Leave-one-out cross-validation (LOOCV) was used to validate the predictive performance of models in the entire dataset.

Results: The optimal clinical model achieved an area under the curve (AUC) of 0.767 [95% confidence interval (CI): 0.638, 0.896] and an accuracy of 0.771 after LOOCV. The AUCs of the best KW + SVM, KW + LR, RFE + SVM, and RFE + LR radiomics models were 0.816, 0.826, 0.853, and 0.850, respectively, and the corresponding AUCs after LOOCV were 0.780, 0.785, 0.755, and 0.772, respectively. The AUC and accuracy after LOOCV of the optimal combined model was 0.804 (95% CI: 0.694, 0.915) and 0.814, respectively. The Delong test showed a statistical difference in predictive performance between the optimal clinical and combined models after LOOCV (Z = 2.003, P = 0.045). The decision curve analysis showed that the combined model performs better than the clinical model.

Conclusion: The CECT radiomics models have a favorable predictive performance in predicting VGPR of high-risk neuroblastoma to neoadjuvant chemotherapy. When integrating radiomics features and clinical features, the predictive performance of the combined models can be further improved.

Citing Articles

Artificial intelligence can help individualize Wilms tumor treatment by predicting tumor response to preoperative chemotherapy.

Nashat A, Alksas A, Aboulelkheir R, Elmahdy A, Khater S, Balaha H Investig Clin Urol. 2025; 66(1):47-55.

PMID: 39791584 PMC: 11729221. DOI: 10.4111/icu.20240135.


The relationship between contrast-enhanced computed tomography radiomics features and mitosis karyorrhexis index in neuroblastoma.

Chen X, Wang H, Xia Y, Shi F, He L, Liu E Discov Oncol. 2024; 15(1):201.

PMID: 38822860 PMC: 11144178. DOI: 10.1007/s12672-024-01067-0.


Predicting response of hepatoblastoma primary lesions to neoadjuvant chemotherapy through contrast-enhanced computed tomography radiomics.

Yang Y, Wang H, Si J, Zhang L, Ding H, Wang F J Cancer Res Clin Oncol. 2024; 150(5):223.

PMID: 38691204 PMC: 11063102. DOI: 10.1007/s00432-024-05746-x.


Application of Machine Learning and Deep EfficientNets in Distinguishing Neonatal Adrenal Hematomas From Neuroblastoma in Enhanced Computed Tomography Images.

Xie L, Gong Y, Dong K, Shen C, Duan B, Dong R World J Oncol. 2024; 15(1):81-89.

PMID: 38274719 PMC: 10807921. DOI: 10.14740/wjon1744.


A narrative review of radiomics and deep learning advances in neuroblastoma: updates and challenges.

Wang H, Chen X, He L Pediatr Radiol. 2023; 53(13):2742-2755.

PMID: 37945937 DOI: 10.1007/s00247-023-05792-6.

References
1.
Goldsby R, Matthay K . Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs. 2004; 6(2):107-22. DOI: 10.2165/00148581-200406020-00004. View

2.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

3.
Qi Y, Zhan J . Roles of Surgery in the Treatment of Patients With High-Risk Neuroblastoma in the Children Oncology Group Study: A Systematic Review and Meta-Analysis. Front Pediatr. 2021; 9:706800. PMC: 8548868. DOI: 10.3389/fped.2021.706800. View

4.
Feng L, Lu X, Yang X, Kan Y, Sun D, Wang W . An F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System. Eur J Radiol. 2022; 154:110444. DOI: 10.1016/j.ejrad.2022.110444. View

5.
Delforge X, De Cambourg P, Defachelles A, Haffreingue A, Rod J, Kassite I . Unresectable thoracic neuroblastic tumors: Changes in image-defined risk factors after chemotherapy and impact on surgical management. Pediatr Blood Cancer. 2021; 68(12):e29260. DOI: 10.1002/pbc.29260. View